IN8bio: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
'''IN8bio''' (formerly '''Incysus Therapeutics''') is a biomedical company specializing in the development of gamma-delta T cell therapies for the treatment of cancer. The business is based on research conducted by [[Lawrence Lamb]] at [[UAB Comprehensive Cancer Center]] and H. Trent Spencer of the Emory University School of Medicine. Its patents are shared with [[UAB]], Emory University and Children's Healthcare of Atlanta. The company adopted its current name in August [[2020]]. | '''IN8bio''' (formerly '''Incysus Therapeutics''', Nasdaq '''INAB''') is a biomedical company specializing in the development of gamma-delta T cell therapies for the treatment of cancer. The business is based on research conducted by [[Lawrence Lamb]] at [[UAB Comprehensive Cancer Center]] and H. Trent Spencer of the Emory University School of Medicine. Its patents are shared with [[UAB]], Emory University and Children's Healthcare of Atlanta. The company adopted its current name in August [[2020]]. | ||
Lamb and Spencer were joined in the founding of the business in [[2017]] by CEO William Ho. Ho maintains a business office for IN8bio on Madison Avenue in New York City. The company's laboratories, long-time tenants at the [[Innovation Depot]], moved to the [[Martin Biscuit Building]] at [[Pepper Place]] in [[2021]]. | Lamb and Spencer were joined in the founding of the business in [[2017]] by CEO William Ho. Ho maintains a business office for IN8bio on Madison Avenue in New York City. The company's laboratories, long-time tenants at the [[Innovation Depot]], moved to the [[Martin Biscuit Building]] at [[Pepper Place]] in [[2021]]. | ||
The company went public on the Nasdaq exchange on [[July 30]], [[2021]]. | |||
==References== | ==References== | ||
* Hansen, Jeff (May 4, 2017) "UAB spinoff targets cancer with drug-resistant immunotherapy, a novel approach to fighting tumors." ''UAB News'' | * Hansen, Jeff (May 4, 2017) "UAB spinoff targets cancer with drug-resistant immunotherapy, a novel approach to fighting tumors." ''UAB News'' | ||
* Van der Bijl, Hanno (January 22, 2021) "IN8bio moving out of Innovation Depot to new space at Pepper Place." {{BBJ}} | * Van der Bijl, Hanno (January 22, 2021) "IN8bio moving out of Innovation Depot to new space at Pepper Place." {{BBJ}} | ||
* "IN8bio launches public offering on Nasdaq." (August 6, 2021) {{BBJ}} | |||
==External links== | ==External links== | ||
Revision as of 16:06, 6 August 2021
IN8bio (formerly Incysus Therapeutics, Nasdaq INAB) is a biomedical company specializing in the development of gamma-delta T cell therapies for the treatment of cancer. The business is based on research conducted by Lawrence Lamb at UAB Comprehensive Cancer Center and H. Trent Spencer of the Emory University School of Medicine. Its patents are shared with UAB, Emory University and Children's Healthcare of Atlanta. The company adopted its current name in August 2020.
Lamb and Spencer were joined in the founding of the business in 2017 by CEO William Ho. Ho maintains a business office for IN8bio on Madison Avenue in New York City. The company's laboratories, long-time tenants at the Innovation Depot, moved to the Martin Biscuit Building at Pepper Place in 2021.
The company went public on the Nasdaq exchange on July 30, 2021.
References
- Hansen, Jeff (May 4, 2017) "UAB spinoff targets cancer with drug-resistant immunotherapy, a novel approach to fighting tumors." UAB News
- Van der Bijl, Hanno (January 22, 2021) "IN8bio moving out of Innovation Depot to new space at Pepper Place." Birmingham Business Journal
- "IN8bio launches public offering on Nasdaq." (August 6, 2021) Birmingham Business Journal
External links
- IN8bio website